MENU
+Compare
MRSN
Stock ticker: NASDAQ
AS OF
Dec 20, 04:59 PM (EDT)
Price
$1.58
Change
-$0.15 (-8.62%)
Capitalization
196.42M

MRSN Mersana Therapeutics Forecast, Technical & Fundamental Analysis

a developer of antibody drug conjugates to improve patient outcomes in multiple oncology indications

Industry Biotechnology
MRSN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
a Summary for MRSN with price predictions
Dec 20, 2024

MRSN in -18.36% downward trend, sliding for three consecutive days on December 18, 2024

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where MRSN declined for three days, in of 301 cases, the price declined further within the following month. The odds of a continued downward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on December 13, 2024. You may want to consider selling the stock, shorting the stock, or exploring put options on MRSN as a result. In of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for MRSN turned negative on December 13, 2024. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at .

MRSN moved below its 50-day moving average on December 13, 2024 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for MRSN crossed bearishly below the 50-day moving average on December 20, 2024. This indicates that the trend has shifted lower and could be considered a sell signal. In of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The RSI Indicator entered the oversold zone -- be on the watch for MRSN's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where MRSN advanced for three days, in of 278 cases, the price rose further within the following month. The odds of a continued upward trend are .

MRSN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. MRSN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: MRSN's P/B Ratio (188.679) is slightly higher than the industry average of (14.529). P/E Ratio (0.000) is within average values for comparable stocks, (87.563). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.739). MRSN has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.013). P/S Ratio (5.596) is also within normal values, averaging (255.281).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MRSN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
MRSN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

MRSN is expected to report earnings to fall 55.97% to -15 cents per share on February 26

Mersana Therapeutics MRSN Stock Earnings Reports
Q4'24
Est.
$-0.15
Q3'24
Missed
by $0.18
Q2'24
Missed
by $0.03
Q1'24
Beat
by $0.02
Q4'23
Beat
by $0.05
The last earnings report on November 13 showed earnings per share of -34 cents, missing the estimate of -17 cents. With 2.73M shares outstanding, the current market capitalization sits at 196.42M.
A.I. Advisor
published General Information

General Information

a developer of antibody drug conjugates to improve patient outcomes in multiple oncology indications

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
840 Memorial Drive
Phone
+1 617 498-0020
Employees
123
Web
https://www.mersana.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ABRFX15.540.24
+1.57%
DSS AmericaFirstMonthlyRisk-OnRisk-Off A
ETAHX32.600.46
+1.43%
Eventide Healthcare & Life Sciences A
GSVUX16.730.19
+1.15%
Goldman Sachs Large Cap Value R6
DIGGX100.170.84
+0.85%
Invesco Discovery R5
JHJIX23.00-1.97
-7.88%
JHancock ESG Large Cap Core I

MRSN and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, MRSN has been loosely correlated with CRNX. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if MRSN jumps, then CRNX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MRSN
1D Price
Change %
MRSN100%
-8.05%
CRNX - MRSN
42%
Loosely correlated
+1.63%
VRDN - MRSN
40%
Loosely correlated
+1.60%
IPSC - MRSN
38%
Loosely correlated
+4.76%
AVTX - MRSN
38%
Loosely correlated
-1.87%
BEAM - MRSN
38%
Loosely correlated
+8.04%
More